Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

The results were published in The Lancet Diabetes and Endocrinology on 21 June. Ecnoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist analogue, similar to the blockbuster obesity drug ...

The obesity drug liraglutide cut migraine days in half in a small trial, though more research is needed to exclude the placebo effect, researchers said.

An innovative weight-loss medication called SANA has shown promising results in early trials, offering hope in the fight ...

In this study, in order to elucidate the action mechanism of traditional Chinese medicines (TCMs) that exhibit clinical efficacy for type II diabetes mellitus (T2DM), an integrated protocol that ...

Recently, timed-release bromocriptine (Cycloset), a sympatholytic dopamine D 2 receptor agonist, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure compared with the healthy population. In recent landmark clinical trials, sodium-glucose co-transporter 2 (SGLT2 ...

A new potential drug treatment for people with type 2 diabetes and obesity lowers blood sugar and increases fat burning.

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the ...

Lower blood sugar and increased fat burning—without negatively affecting appetite or muscle mass. These are some of the most ...